MediWound Ltd.

MDWD
NASDAQ
Last Updated: 9/28/2022 1:53:59 PM
Price
1.415
Changes
0.04
% Change
3.28
Volume
11580
52 Week
High
4.01
52 Week
Low
1.21
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MediWound Ltd. Company Details
CEO:   Mr. Sharon Malka
Country:   IL
Industry:   Biotechnology
Website:   https://www.mediwound.com
Exchange:   NASDAQ Global Market
IPO\Launch Date:   2014-03-20
MediWound Ltd. Company Executive Details
  Mr. Stephen T. Wills CPA, CPA, MST
  Executive Chairman
  Dr. Ety Klinger
  Chief R&D Officer
  Mr. Yaron Meyer
  Executive Vice President, Gen. Counsel & Corporation Sec.
  Mr. Boaz Gur-Lavie CPA, M.B.A.
  Chief Financial Officer
  Prof. Lior Rosenberg M.D.
  Co-Founder & Chief Medical Technology Officer

MediWound Ltd. Latest News

MediWound Ltd. (MDWD) CEO Ofer Gonen on Q2 2022 Results - Earnings Call Transcript


MediWound Ltd. (NASDAQ:MDWD ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Monique Kosse - Investor Relations Ofer Gonen - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Bryan Bergin - Cowen Ryan Zimmerman - BTIG Arthur He - H.C.


Published on: 2022-08-10 00:31:03

Impact on Symbol / Company: MDWD

View News

MediWound Schedules Second Quarter 2022 Financial Results


Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET


Published on: 2022-08-01 08:00:00

Impact on Symbol / Company: MDWD

View News

MediWound Ltd. (MDWD) CEO Sharon Malka on Q1 2022 Results - Earnings Call Transcript


MediWound Ltd. (NASDAQ:MDWD ) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Monique Kosse - IR Sharon Malka - CEO Boaz Gur-Lavie - Chief Financial Officer Ofer Gonen - Board Member Lior Rosenberg - Chief Medical Officer Cyaandi R.


Published on: 2022-05-17 12:04:10

Impact on Symbol / Company: MDWD

View News

MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates


MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 1.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?


Published on: 2022-05-17 09:47:17

Impact on Symbol / Company: MDWD

View News

MediWound Posts Promising EscharEx Data For Chronic Wounds


MediWound Ltd (NASDAQ: MDWD) has announced results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers (VLUs).  The study met its primary and secondary endpoints and wound closure safety measurements.


Published on: 2022-05-12 07:37:04

Impact on Symbol / Company: MDWD

View News

MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022


YAVNE, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the first quarter ended March 31, 2022 on Tuesday, May 17, 2022.


Published on: 2022-05-10 16:01:00

Impact on Symbol / Company: MDWD

View News

MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022


Results Highlight the Safety and Efficacy in Hard-to-Heal Wounds


Published on: 2022-03-29 08:00:00

Impact on Symbol / Company: MDWD

View News

MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2021 Results - Earnings Call Transcript


MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2021 Results - Earnings Call Transcript


Published on: 2022-03-17 12:31:09

Impact on Symbol / Company: MDWD

View News

MediWound (MDWD) Reports Q4 Loss, Misses Revenue Estimates


MediWound (MDWD) delivered earnings and revenue surprises of 6.25% and 2.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?


Published on: 2022-03-17 09:47:15

Impact on Symbol / Company: MDWD

View News

MediWound to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022


YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2021 on Thursday, March 17 2022.


Published on: 2022-03-10 08:00:00

Impact on Symbol / Company: MDWD

View News

MediWound to Present at Upcoming Investor Conferences in February


YAVNE, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming investor conferences in February. Details for each is as follows:


Published on: 2022-02-14 09:03:00

Impact on Symbol / Company: MDWD

View News

MediWound's EscharEx Mid-Stage Trial Meets Primary Goal In Venous Leg Ulcers


MediWound Ltd (NASDAQ: MDWD) has posted topline results from its U.S. Phase 2 study of EscharEx for the debridement (removal of dead or infected skin tissue for wound healing) of venous leg ulcers (VLUs).  The study randomized 120 patients, of which 119 patients were treated by either EscharEx (n=46), a gel vehicle (n=43), or a non-surgical standard-of-care consisting of either enzymatic or autolytic debridement (n=30).


Published on: 2022-01-24 07:13:20

Impact on Symbol / Company: MDWD

View News

Grow your Money

We helps you in understanding the science behind growing the money, which will help you diversify your funds as per your requirements and helps in achieving your retirement goals, children education, investment in property, business or any smart looking startup ventures

Services we Offer

We offer several services including expert recommendations & suggestions on buying ETF, Mutual Funds, Bonds, Debt securities, Equities, Property invesments and several others

Live Market Data

We provide you live market data for your analysis, review and looking out for quick buying opportunities to help you